Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice! Thanks for the post
Elanco, Aratana Announce Marketing Authorization of GALLIPRANT® (grapiprant tablets) in Europe
LEAWOOD, Kan., Jan. 11, 2018 /PRNewswire/ -- Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. (NASDAQ: PETX), today announced the European Commission adopted the decision to grant marketing authorization of GALLIPRANT® (grapiprant tablets) in the European Union.
Galliprant is a new veterinary medicine that will be indicated for the treatment of pain associated with mild to moderate osteoarthritis in dogs. Grapiprant, the active ingredient in Galliprant, is a non-steroidal non-cyclooxygenase inhibiting anti-inflammatory drug. Elanco has exclusive rights to develop, manufacture, market and commercialize Galliprant globally, and it co-promotes the product with Aratana in the United States.
About Elanco Animal Health
Elanco provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries around the world. We value innovation, both in scientific research and daily operations, and strive to cultivate a collaborative work environment for more than 6,500 employees worldwide. Together with our customers, we are committed to raising awareness about global food security, and celebrating and supporting the human-animal bond. Founded in 1954, Elanco is a division of Eli Lilly and Company. Our worldwide headquarters and research facilities are located in Greenfield, Indiana (U.S.). Visit us at www.elanco.com or www.elancoeurope.com.
I hear ya Terry... atleast we moving in the intended direction thru conditional approval... full approval is only one more study away :)
PETX wins conditional approval for treating canine osteosarcoma:
https://finance.yahoo.com/news/aratana-therapeutics-granted-conditional-license-130500431.html
so are you saying that the ADXS vaccine should be approved for dogs, BUT not humans ?? I own ADXS stock and was curious of your thoughts about ADXS
Absolutely not, Biotech2.
ADXS' splendid invention by Prof. Yvonne Paterson is of Nobel quality but has received incredible trashing by know-nothings and is now the object of an effort by clowns to dump it at a rummage sale.
Can anybody name another biotech that has a pivotal trial paid for entirely by a science-savvy women's charity who found its vaccine superior to all others?
The problem I tried to state as plainly as possible is the assignment of the the therapeutic HER2 vaccine to the Agriculture Department for licensing. The hijinks have been an atrocity.
It was a most admirable decision to assign R&D to PETX because of a deadly threat from the antigen. The very successful herceptin drug has been found responsible for a small number of deaths in ladies with breast cancer from heart attacks caused by herceptin killing heart cells expressing the oncogene. Vaccines are much more powerful than [other] drugs since there is no known way to turn them off.
I reckon there is not a dog owner on the planet who would not welcome the chance for life of his dog, whatever the risk, instead of an agonizing death. On the other hand even rabid dog owners can be more sentimental about the life of their wives.
Clear enough, friend?
I have stopped buying ADXS because of the idiots in charge but wish us both well.
Best, Terry
so are you saying that the ADXS vaccine should be approved for dogs, BUT not humans ?? I own ADXS stock and was curious of your thoughts about ADXS
I'm more curious about AT-014
As I see it that is a bureaucratic disgrace that the osteosarcoma vaccine has not already been fully approved while even now it is fighting for only a qualified license after an added test.
The osteosarcoma vaccine is a therapeutic cancer vaccine that had fallen into a rathole as a blacklisted human cancer vaccine so that the owner had various makebelieve names for its human development and it got assigned to the Agriculture Department by the veterinary bureaucracy. The Ag boys don't know from nothing about a therapeutic vaccine. They are quite familiar with routine prophylactic vaccines.
Not that I would ever want to say any mean things about bureaucrats which I once was.
PETX and ADXS [the owner of the osteosarcoma vaccine] have wasted a lot of energy yelling at each other because they can't yell at the regulators who hold them by the throat.
Best, Terry
I'm more curious about AT-014, and PETX has so much more in the pipeline, so no worries on ST-014 failure
Aratana Therapeutics Announces Study Results for AT-016
On December 14, 2017, Aratana's license partner responsible for the development of AT-016 shared the results of a pivotal study, which did not achieve protocol-defined efficacy success criteria. As part of Aratana's exclusive commercial license for dogs with osteoarthritis in the United States, Aratana had funded the clinical study and other work. Aratana anticipates that after its license partner has further evaluated the study results, the parties will determine if the collaboration to bring the therapeutic to market will continue.
https://tinyurl.com/yagmm4p4
I was a bit - just a bit - surprised since Mike West's agglomeration of companies are working miracles - wouldn't curing the blind qualify? - but many others are stumbling.
I guess the lesson is if you want something done do it yourself?
Don't confuse that with Galliprant. Galliprant is also a true wonder drug from our own experience with our dog's osteoarthritis.
Best, Terry
Indeed. It's starting to creep (well plummet) awfully close to the 52 week low
Glad I shorted this a few weeks ago.
Glad PETX saved our dog's life.
Not a good reason for buying?
Actually there are those, especially huge longterm winners, who advise buying what you know.
Just coincidence in our case. We probably would not have ever heard of Galliprant if we didn't own the stock.
In the future I expect PETX to be a huge winner with the novel idea of an actual pet biotech at a fortuitous time but elephant hunting can get you trampled.
Best, Terry
Glad I shorted this a few weeks ago. Just got back in as I feel this will bounce back up some.
at least the management is smart enough to realize they made a dumb decision and do a 180 ??
Sounds like management is a little short when it comes to common sense , glad I dumped at $7.05 ;) PETX
Wow that was pretty sneaky of management
Hilarious!
Not many managements plan stupid moves.
Was the secondary stupid?
-It most certainly was if they didn't expect the reaction in this befuddled market that has the incredibly naive notion only an increase in share count is dilution.
- And they obviously didn't.
I would bet there is a lot of short covering - at a loss.
Best, Terry
Wow that was pretty sneaky of management to announce an offering , let the price plummet so there short buddies could cover , then pull the offering ;) WHAT AN OBVIOUS SCAM , just another Co sticking the rusty knife in the investors backs , GARBAGE STOCK AND MANAGEMENT PETX
Good vibrations are back :)
Dang. They misbehaved, market backhanded them, and they apologized and went to their room for time out...
Course, long term they need money so it’ll be interesting to see what they do.
Holding long term here.
Previcox was the drug we first got from our vet for our border collie mix.
It does appear this NSAID is cheaper by mail order but comparisons are difficult and pointless for us because it is vastly inferior to Galliprant from what we can see. Galliprant is most assuredly not an NSAID and is now in R&D for humans.
Side Effects of Previcox for Dogs
(Galliprant's) sitting stagnant on shelves at the price point they have it at right now.
Sam,
Would appreciate it if you explain this more.
I certainly don't mean to be argumentative but we had two german shepherds die painful deaths, especially the second beautiful full-blooded shepherd who died a particularly heart-rending death from osteoarthritis.
My wife got a more expensive, dangerous drug from our vet for our severely crippled, youngish border collie/labrador mix that helped somewhat like drugs in the past but it doesn't begin to compare with the maintenance doses of Galliprant that I got only with considerable trouble in our rural area.
I am having trouble being sure of the name of the first drug.
As a maintenance drug, Galliprant is more expensive than a short time fix.
Again Galliprant [a prostaglandin is not properly called an NSAID since it is both an anti-inflammatory and promoter of inflammation to fight disease. I suspect such a complexity was the reason prostaglandin sat on the laboratory shelves for a decade ot two without trials and why Eli Lilly chose PETX to experiment with the drug for dogs instead of its own veterinary subsidiary.
Contrary opinions solicited because we realize the risk inherent in using a newly approved powerfu drug with a skimpy safety trial.
If Galliprant was selling as well as it was being touted to they should have money rolling in.
Again I consider myself at a great disadvantage questioning a veterinarian's expert opinion but ramp up of human drug sales in America is very slow because of such as advertising wars that appears unique to America. Hopefully the projected admission of Galliprant to marketing in Europe will result in quicker sales ramp up.
Best, Terry
Yeah $35 million doesn't go far in the pharma research industry. If Galliprant was selling as well as it was being touted to they should have money rolling in. But it's not, sitting stagnant on shelves at the price point they have it at right now.
They will HAVE to do this capital raise next year as well. $35 million is pocket change; it should have been at least double...
I shorted Aratana after it ran up a week or two ago and was about to tuck my tail and close out yesterday and decided to wait a few more days and glad I did lol. Still long term potential depending on what the company does moving forward.
They are obviously strapped for cash or they are selling off a lot of their shares and then will announce they sold Galliprant and Entyce off and PETX will tank. Who knows. I was expecting it to drop back for a while but not this way. Interesting to watch what happens here
Oh, I completely agree on future prospects and have this held in my long term hold portfolio...
Just talking about short term. Down 18% or so is a buzzkill on good vibrations, no matter how you cut the long term :)
Man, they sure buzzkilled our good vibrations didn’t they!?
No.
Not in my view.
A small, unprofitable development-stage biotech has to raise money somehow.
There are some handouts but never enough.
I think [hope, pray, whatever] PETX has a brilliant future but it will get nowhere without cash to burn.
PETX's progress on the R&D side has been grand and would be far more spectacular without the nonsensical osteosarcoma vaccine stall from Ag lunkheads who only know prophylactic vaccines and not so much those.
JMO.
Best, Terry
Galliprant works just like other NSAIDS it just targets what we want to hit more specifically
And pills are just pills, Sam?
I note your excellent professional credentials but nevertheless I take exception to your claim Galliprant is just another NSAID.
"Terry, I think you are missing his point, this will be a long, slow slog.."
Biotech Researcher,
I am singularly blessed in having no knowledge of the future. As you know, the ancient one-eyed cyclops were cursed by the gods with certain knowledge of the exact time of their death.
I don't how all you good people know the future certain but I am spared all of that pain.
Looks to this moron like Aratana is way beyond all the doomsday talk but what do I know?
- Ans: Nothing.
Great weekend, everyone.
Best, Terry
Thanks for your thoughts as well. I agree it's under valued, I just worry it may take a while for the value to catch up as they've got to make the numbers work better first before we see it pop.
Galliprant works just like other NSAIDS it just targets what we want to hit more specifically so less long term sides and it can be used on patients with some conditions that keep us from using other NSAIDS. If Elanco can get the price down close to what Rimadyl is then I think it will start moving off the shelves a lot quicker. There are generics of Rimadyl now for half the price and that's what a lot of clinics use so when you compare generic Carprofen to Galliprant it's a HUGE price difference per month. Once that gap closes the sales will pick up for Galliprant without a doubt
Thanks Sam. I understand. Most of my Galliprant info is from the reviews that state things like "I got my dog back", "yesterday my dog couldn't stand but today he's climbing the stairs", etc...
I agree that with Elanco mfg now the costs should come down. I also still think the stock is undervalued because of their pipeline and catalysts coming but...I chart. And it's just too overbought at the moment.
Thanks for you insight Sam
BlueRyan, I know I guess I didn't word that well enough on my post. I was actually in between surgeries when I posted that. I'm a vet so I'm very familiar with their products.
Biotech and I are on the same page, I think Galliprant is a great product, I have a few patients on it that I can't use other meds on and it's great for that. However it's very expensive compared to other NSAIDs. I work at a high end clinic in a very wealthy area and still have clients that don't want to make the switch because of the cost. Cost is always a huge factor in veterinary medicine that is not an issue in human medicine. The price will come down with time but Galliprant is moving slow off my shelves right now. Big brother is pushing it hard but from myself and other vets I've spoke to we all see the same thing, very slow sales.
Same thing with Entyce, i actually don't even stock it as I have other appetite stimulants that work great that have been used for years and years and are dirt cheap.
Not nocking any of their products, I'm just saying with the pricing and my experience in the vet industry I don't think there's going to be a big price surge for Aratana anytime soon and I don't think a buyout is going to be anytime soon either. I think Aratana is long term play but short term expect it to stay around this range for a while and probably dip back down before it makes another step up again.
Sam
Galliprant has nothing to do with appetite. Entyce does. Galliprant EU approval will be big. Revs in 2018 will grow and Elanco will foot the mfg bill. Costs or not Galliprant is giving people's dogs a new lease on quality of life. Nevertheless, the stock is in overbought territory
Cheers
Terry, I think you are missing his point, this will be a long, slow slog..
I think Aratana is definitely making the right moves but they've got a big battle to fight to make Galliprant successful.
Hi, Sam.
Elanco, Aratana Announce Positive Opinion on GALLIPRANT(R) (grapiprant tablets) in Europe
LEAWOOD, Kan., Nov. 10, 2017 /PRNewswire/ -- Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. (NASDAQ: PETX), today announced the European Medicine Agency's (EMA) Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion to recommend the marketing authorization of GALLIPRANT(R) (grapiprant tablets) in the European Union. Following the positive opinion, the European Commission will complete the regulatory process for a final decision on the Marketing Authorisation in early 2018.
http://tinyurl.com/ya4bc8us
Looks to me like Big Brother could handle the sales pitch quite adequately without the pixie partner.
Galliprant is huge for us because it may be a longterm lifesaver for our youngish border collie mix. It has made a huge difference for the little darlin but even more important Eli Lilly used a drug that has been around for a very long time but never trialed.
Eli Lilly chose PETX for the R&D despite having its own billion dollar vet subsidiary.
Beyond that, Eli Lilly used the PETX trials and approval as a testbed for a human drug. My wife is very badly crippled with osteoarthritis and is terrified of knee surgery. She may or may not be able to wait for the human galliprant but from our experience it is huge,
The ghrelin-lite appetite stimulant is the opposite - a takeoff on an approved human drug.
That doesn't answer the question of whether some non-approved dog appetite stimulants aren't just as good.
I have no real good answer but we had a very skinny german shepherd, the last remainder of a litter of "german-shepherd type" in a rescue shelter. Rosie grew up to be a beautiful, slender full-blooded german shepherd from all appearances. One kennel owner who kept the dog occasionallytried her level best to put some meat on Rosie's bones but failed miserably.
Good luck to you and thanks for your thoughts.
Best, Terry
Sam, I agree 100% on what you stated. The sales growth will be slow...
Terry, I think Aratana is definitely making the right moves but they've got a big battle to fight to make Galliprant successful. It's been hard to move off the shelves due to the cost. There are plenty non FDA-approved appetite stimulants in the vet world that have been used successfully since before I was alive that are very cheap. I think they will have to be bought out to stand a chance at surviving but that will also depend on how the partnership and sales go I'm sure. Definitely a company to keep an eye on but I think it'll be at least a year or two until things really start moving
A Dog of a Stock Suddenly Jumps Up and No One Notices
From the earnings conference call, selected excerpts.
http://tinyurl.com/ybtjpft7
With GALLIPRANT, we've been working very closely with our marketing collaborator, Elanco Animal Health, a division of Eli Lilly and Company. Well, Aratana developed GALLIPRANT from a clinical proof of concept through FDA approval; we signed a landmark collaboration with Elanco in 2016. That collaboration puts our emerging sales force alongside Elanco’s factor of 10 larger sales force and a comprehensive network of distributors as we entered the competitive multi-100 million dollar canine osteoarthritis pain market in the United States.
For the record, there is a hint in my mind of a future takeover here but this tired speculation everywhere these days with small development-stage biotechs seems contradicted by other factors.
I really, really like Entyce but again looky here:
We are also working directly with several national and regional corporate customers, which we believe constitute approximately 10% of all veterinary clinics in the US. Hence we believe that ENTYCE is well represented and the competitive issues will be manageable because ENTYCE is the only FDA approved appetite stimulant in dogs.
This is obviously a case where the resources of a huge corporation would be a terrific advantage, not to mention the time factor. Success with Entyce could obviously entice a horde of new ghrelin copycats in a field where FDA approval is not necessary but PETX does not seem deterred in the slightest from building its own sales organization.
Third and finally, AT-016, allogeneic adipose-derived stem cells for dogs...
And on to a brave new world where no veterinary operation ever went before.
That was all from the introductory remarks of the CEO. Others might want to read more from a dog that could start barking very loudly.
Not that I am biased or anything.
Best, Terry
Dogs once on kill lists now Harvey heroes
http://itandus.com/2017/08/dogs-once-on-kill-lists-now-harvey-heroes/
On Topic dammit.
You see our indoor tornado like all border collie pups was not as energetic as a jack russel terrier which is only exceeded on earth for energy by a lightning bolt. But the terrier is not nearly as destructive as our rocket was.
The world's smartest dog(?} served a purpose besides taking a chunk out of an abused oversize german shepard's ear for trying to eat out of her dish and doing a lot of rewiring. She was a local guinea pig for the osteoarthritis drug PETX took through approval for Eli Lilly.
Wonderful drug but no cure. It eliminates the pain without destroying the synovial fluids in the joints. No other pain reliever does that.
Some ugly, even disqualifying, side effects could yet make their presence known in mass marketing now in process but none is yet evident.
I expect PETX may run like a greyhound soon but then I have gotten a certain bias from Galliprant.
Best, Terry
Looks like bottom is in , hoping it heads north to $8 only hold 300 shares at $5.42 ;) GLTY $andman , nothing wrong with a quick buck ;)
Lol sandman, you in PETX as well? I own PETX also
Heading back up , reversal in effect, double bottom is in , time to make some $$$$$$PETX
I like what I see ;) grabbed a stash yesterday !! LETS ROLL $ANDMAN
Followers
|
24
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
438
|
Created
|
08/09/13
|
Type
|
Free
|
Moderators |
Corporate Headquarters
1901 Olathe Blvd
Kansas City, Kansas 66103
(913) 951-2132
Other Locations
200 Clarendon Street; 54th Floor
Boston, Massachusetts 02116
(617) 425-9226
Business Development Contacts
Julia A. Stephanus
Chief Commercial Officer
(913) 951-2139
juliaastephanus@aratana.com
Erick J. Lucera, CPA, CFA
Vice President, Corporate Development
(913) 951-2136
erickjlucera@aratana.com
Investor and Media Contacts
Tiberend Strategic Advisors, Inc.
35 West 35th Street; 11th Floor
New York, New York 10001
(212) 827-0020
Investors - Joshua Drumm, PhD
(212) 375-2665
jdrumm@tiberend.com
Media - Andrew Mielach
(212) 375-2694
amielach@tiberend.com
Transfer Agent and Registrar
American Stock Transfer & Trust Company, LLC.
(800) 937-5449
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |